Abstract
Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.
| Original language | English |
|---|---|
| Pages (from-to) | 398-404 |
| Number of pages | 7 |
| Journal | Histopathology |
| Volume | 45 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 2004 |
Fingerprint
Keywords
- CD117
- Hodgkin's lymphoma
- KIT
- Non-Hodgkin's lymphoma
- Tissue microarray
ASJC Scopus subject areas
- Anatomy
- Pathology and Forensic Medicine
- Cell Biology
Cite this
Rare expression of KIT (CD117) in lymphomas : A tissue microarray study of 1166 cases. / Zimpfer, A.; Went, P.; Tzankov, A.; Pehrs, A. C.; Lugli, A.; Maurer, R.; Terracciano, L.; Pileri, S.; Dirnhofer, Stephan.
In: Histopathology, Vol. 45, No. 4, 10.2004, p. 398-404.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rare expression of KIT (CD117) in lymphomas
T2 - A tissue microarray study of 1166 cases
AU - Zimpfer, A.
AU - Went, P.
AU - Tzankov, A.
AU - Pehrs, A. C.
AU - Lugli, A.
AU - Maurer, R.
AU - Terracciano, L.
AU - Pileri, S.
AU - Dirnhofer, Stephan
PY - 2004/10
Y1 - 2004/10
N2 - Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.
AB - Aims: Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma. Materials and results: Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation. Conclusions: KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.
KW - CD117
KW - Hodgkin's lymphoma
KW - KIT
KW - Non-Hodgkin's lymphoma
KW - Tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=6044252858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=6044252858&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2559.2004.01968.x
DO - 10.1111/j.1365-2559.2004.01968.x
M3 - Article
VL - 45
SP - 398
EP - 404
JO - Histopathology
JF - Histopathology
SN - 0309-0167
IS - 4
ER -